What does Calidi Biotherapeutics, Inc. do?
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for…
What is Calidi Biotherapeutics, Inc.'s P/E and P/B ratio?
Calidi Biotherapeutics, Inc. has a P/E ratio of -0.0 and a P/B ratio of 0.76.
What is Calidi Biotherapeutics, Inc.'s debt-to-equity ratio?
Calidi Biotherapeutics, Inc. has a debt-to-equity ratio of 0.62.
How much does Calidi Biotherapeutics, Inc. owe compared with what it owns?
Calidi Biotherapeutics, Inc. owes $0.57 for every $1 it owns (balance sheet Jun 2026), which is moderate.
What is Calidi Biotherapeutics, Inc.'s Positivity rank?
Calidi Biotherapeutics, Inc. is ranked #2,835 of 6,774 companies globally and #1,031 of 4,000 in United States on PositoAI, with a Positivity Score of 21,103.
Does Calidi Biotherapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
Yes. Calidi Biotherapeutics, Inc. has 1 active red flag (PosiRed) on record: Stock exchange listing-rule deficiency notice (8-K Item 3.01) (dated 25 Sep 2026). It has no yellow flags.
Where can I read the latest news about Calidi Biotherapeutics, Inc.?
Recent headlines about Calidi Biotherapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Calidi Biotherapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Calidi Biotherapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.